CERUS CORP CERS
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
4/9
Piotroski F — financial health
-13.54
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $233.8M | -$15.6M | — | $1.1M | $65.0M |
| 2024 | $201.3M | -$20.9M | — | $8.5M | $56.9M |
| 2023 | $186.8M | -$37.5M | — | -$47.8M | $53.4M |
| 2022 | $188.3M | -$42.8M | — | -$27.6M | $68.6M |
| 2021 | $159.5M | -$54.4M | — | -$34.8M | $85.6M |
| 2020 | $114.2M | -$59.9M | — | -$43.4M | $103.8M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.54 (distress)
- Working capital / assets 0.332
- Retained earnings / assets -4.873
- EBIT / assets -0.039
- Equity / liabilities 0.414
Source: SEC EDGAR filings · CIK 0001020214 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.